Skip to main content
SpringerLink
Log in

Prognostic utility of serum vitronectin levels in acute myocardial infarction

Prognostischer Nutzen des Vitronectin-Serumspiegels bei akutem Herzinfarkt

  • e-Herz: Original article
  • Published:
Herz Aims and scope Submit manuscript

Abstract

Background

Vitronectin (VN) functions as a regulator of platelet adhesion and aggregation, coagulation, and fibrinolysis. The aim of this study was to assess the prognostic significance of serum VN levels in patients with acute myocardial infarction (MI).

Methods

In this study 62 patients admitted with ST-elevation myocardial infarction (STEMI), or non-ST-elevation myocardial infarction (NSTEMI) were enrolled. Serum VN levels were measured within 6 h after onset of chest pains.

Results

The VN serum levels were higher in MI patients with a mean of 2.257 µg/ml (range 1.541–4.493 µg/ml) in the STEMI group, 1.785 µg/ml (range 1.372–4.113 µg/ml) in the NSTEMI group, and 1.222 µg/ml (range 1.033–1.466 µg/ml) in the controls (p = 0.012). Major adverse cardiovascular events could be predicted at 6 months using VN levels independently of other variables [odds ratio (OR) 9.87, 95 % confidence interval (CI) 2.54–47.37, p = 0.001]. There was a significant positive correlation between VN levels and the Gensini score in NSTEMI patients (r = 0.436, p = 0.013).

Conclusion

The VN level may be relevant as a clinical biomarker for adverse cardiovascular outcomes not only in patients with ischemic heart disease undergoing coronary interventions, as previously reported, but also in coronary artery disease patients presenting with acute MI.

Zusammenfassung

Hintergrund

Vitronectin (VN) ist ein Regulator der Thrombozytenadhäsion und -aggregation, der Koagulation und Fibrinolyse. Ziel der vorliegenden Studie war es, die prognostische Bedeutung des VN-Serumspiegels bei Patienten mit akutem Myokardinfarkt (MI) zu ermitteln.

Methoden

An dieser Studie nahmen 62 Patienten teil, die wegen ST-Strecken-Hebungs-Infarkt (STEMI) oder Nicht-ST-Strecken-Hebungs-Infarkt (NSTEMI) stationär aufgenommen worden waren. Dabei wurde der VN-Serumspiegel innerhalb von 6 h nach Beginn der Thoraxschmerzen bestimmt.

Ergebnisse

Bei Patienten mit MI war der VN-Serumspiegel mit einem Durchschnittswert von 2,257 µg/ml (Spannbreite: 1,541–4,493 µg/ml) in der STEMI-Gruppe höher als in der NSTEMI-Gruppe mit 1,785 µg/ml (Spannbreite: 1,372–4,113 µg/ml) und bei den Kontrollen mit 1,222 µg/ml (Spannbreite: 1,033–1,466 µg/ml; p = 0,012). Größere unerwünschte kardiovaskuläre Ereignisse innerhalb von 6 Monaten konnten anhand der VN-Werte unabhängig von anderen Variablen prognostiziert werden [Odds Ratio (OR): 9,87; 95%-Konfidenzintervall (95%-KI): 2,54–47,37; p = 0,001). Es bestand bei NSTEMI-Patienten eine signifikante positive Korrelation zwischen dem VN-Wert und dem Gensini-Score (r = 0,436; p = 0,013).

Schlussfolgerung

Relevanz weist der VN-Wert als klinischer Biomarker für ungünstige kardiovaskuläre Verläufe möglicherweise nicht nur bei Patienten mit ischämischer Herzerkrankung auf, bei denen – wie bereits früher berichtet – eine Koronarintervention erfolgt, sondern auch bei Patienten mit koronarer Herzkrankheit und akutem MI.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Schvartz I, Seger D, Shaltiel S (1999) Vitronectin. Int J Biochem Cell Biol 31:539–544

    Article  CAS  PubMed  Google Scholar 

  2. Preissner KT, Seiffert D (1998) Role of vitronectin and its receptors in hemostasis and vascular remodeling. Thromb Res 89:1–21

    Article  CAS  PubMed  Google Scholar 

  3. Fay WP, Parker AC, Ansari MN et al (1999) Vitronectin inhibits the thrombotic response to arterial injury in mice. Blood 93:1825–1830

    CAS  PubMed  Google Scholar 

  4. Zhuang P, Blackburn MN, Peterson CB (1996) Characterization of the denaturation and renaturation of human plasma vitronectin: I. Biophysical characterization of protein unfolding and multimerization. J Biol Chem 271:14323–14332

    Article  CAS  PubMed  Google Scholar 

  5. Preissner KT, Reuning U (2011) Vitronectin in vascular context: facets of a multitalented matricellular protein. Semin Thromb Hemost 37:408–424

    Article  CAS  PubMed  Google Scholar 

  6. Seiffert D (1997) Constitutive and regulated expression of vitronectin. Histol Histopathol 12:787–797

    CAS  PubMed  Google Scholar 

  7. Seiffert D, Geisterfer M, Gauldie J et al (1995) IL-6 stimulates vitronectin gene expression in vivo. J Immunol 155(6):3180–3185

    CAS  PubMed  Google Scholar 

  8. Van Aken BE, Seiffert D, Thinnes T, Loskutoff DJ (1997) Localization of vitronectin in the normal and atherosclerotic human vessel wall. Histochem Cell Biol 107(4):313–320

    Article  Google Scholar 

  9. Niculescu F, Rus HG, Vlaicu R (1987) Immunohistochemical localization of C5b-9, S-protein, C3d and apolipoprotein B in human arterial tissues with atherosclerosis. Atherosclerosis 65(1–2):1–11

  10. Guettier C, Hinglais N, Bruneval P et al (1989) Immunohistochemical localization of S protein/vitronectin in human atherosclerotic versus arteriosclerotic arteries. Virchows Arch A Pathol Anat Histopathol 414:309–313

    Article  CAS  PubMed  Google Scholar 

  11. Dufourcq P, Louis H, Moreau C et al (1998) Vitronectin expression and interaction with receptors in smooth muscle cells from human atheromatous plaque. Arterioscler Thromb Vasc Biol 18:168–176

    Article  CAS  PubMed  Google Scholar 

  12. Ekmekci H, Sonmez H, Ekmekci OB et al (2002) Plasma vitronectin levels in patients with coronary atherosclerosis are increased and correlate with extent of disease. J Thromb Thrombolysis 14:221–225

    Article  CAS  PubMed  Google Scholar 

  13. Derer W, Barnathan ES, Safak E et al (2009) Vitronectin concentrations predict risk in patients undergoing coronary stenting. Circ Cardiovasc Interv 2:14–19

    Article  PubMed  Google Scholar 

  14. Thygesen K, Alpert JS, Jaffe AS et al (2012) Third universal definition of myocardial infarction. Eur Heart J 33:2551–2567

    Article  PubMed  Google Scholar 

  15. Ekmekci OB, Ekmekci H (2006) Vitronectin in atherosclerotic disease. Clin Chim Acta 368:77–83

    Article  CAS  PubMed  Google Scholar 

  16. Thiagarajan P, Kelly KL (1988) Exposure of binding sites of vitronectin on platelets following stimulation. J Biol Chem 263:3035–3038

    CAS  PubMed  Google Scholar 

  17. Asch E, Podack E (1990) Vitronectin binds to activated human platelets and plays a role in platelet aggregation. J Clin Invest 85:1372–1378

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Mohri H, Ohkubo T (1991) How vitronectin binds to activated glycoprotein IIb/IIIa complex and its function in platelet aggregation. Am J Clin Pathol 96:605–609

    CAS  PubMed  Google Scholar 

  19. Sinning C, Lillpopp L, Appelbaum S et al (2013) Angiographic score assessment improves cardiovascular risk prediction: the clinical value of SYNTAX and Gensini application. Clin Res Cardiol 102:495–503

    Article  CAS  PubMed  Google Scholar 

  20. Newall F, Johnston L, Ignjatovic V et al (2009) Age-related plasma reference ranges for two heparin-binding proteins-vitronectin and platelet factor 4. Int J Lab Hematol 6:683–687

    Article  Google Scholar 

Download references

Compliance with ethical guidelines

Conflict of interest. S. Aslan, B. Ikitimur, H.A. Cakmak, B. Karadag, E.Y. Tufekcioglu, H. Ekmekci, and H. Yuksel state that there are no conflicts of interest. All studies on humans described in the present manuscript were carried out with the approval of the responsible ethics committee and in accordance with national law and the Helsinki Declaration of 1975 (in its current, revised form). Informed consent was obtained from all patients included in studies.

Author information

Authors and Affiliations

  1. Cerrahpasa Medical Faculty, Department of Cardiology, Istanbul University, Istanbul, Turkey

    S. Aslan, B. Ikitimur, H.A. Cakmak, B. Karadag & H. Yuksel

  2. Cerrahpasa Medical Faculty, Department of Public Health, Istanbul University, Istanbul, Turkey

    E.Y. Tufekcioglu

  3. Cerrahpasa Medical Faculty, Department of Biochemistry, Istanbul University, Istanbul, Turkey

    H. Ekmekci

Authors
  1. S. Aslan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Ikitimur
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H.A. Cakmak
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. Karadag
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E.Y. Tufekcioglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H. Ekmekci
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H. Yuksel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B. Karadag.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aslan, S., Ikitimur, B., Cakmak, H. et al. Prognostic utility of serum vitronectin levels in acute myocardial infarction. Herz 40, 685–689 (2015). https://doi.org/10.1007/s00059-014-4105-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00059-014-4105-2

Keywords

Schlüsselwörter

Search

Navigation